- Home
- REXR vs LEGN Comparison
REXR vs LEGN Comparison
Compare REXR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REXR | LEGN |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 5.9B |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | REXR | LEGN |
|---|---|---|
| Price | $37.45 | $20.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 12 |
| Target Price | $41.00 | ★ $61.33 |
| AVG Volume (30 Days) | ★ 2.0M | 1.7M |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.90% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,003,133,000.00 | N/A |
| Revenue This Year | $0.09 | $42.68 |
| Revenue Next Year | $2.99 | $30.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.13 | N/A |
| 52 Week Low | $32.14 | $16.24 |
| 52 Week High | $44.38 | $37.50 |
Technical Indicators
Market Signals| Indicator | REXR | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 55.10 | 45.09 |
| Support Level | $34.75 | $19.96 |
| Resistance Level | $37.87 | $21.97 |
| Average True Range (ATR) | 0.55 | 0.99 |
| MACD | -0.05 | 0.18 |
| Stochastic Oscillator | 48.90 | 25.86 |
Price Performance
Historical ComparisonAbout REXR Rexford Industrial Realty Inc.
Rexford Industrial Realty Inc is a real estate investment trust focused on owning, operating and acquiring industrial properties in Southern California infill markets. Its goal is to generate attractive risk-adjusted returns for the stockholders by providing superior access to industrial property investments and mortgage debt investments secured by industrial property in high-barrier Southern California infill markets. The company generates revenue from rental income derived from properties in its portfolio.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.